AAAAAA
Results: 1-25/38
Authors:
Marriott, JB
Muller, G
Stirling, D
Dalgleish, AG
Citation: Jb. Marriott et al., Immunotherapeutic and antitumour potential of thalidomide analogues, EXPERT OP B, 1(4), 2001, pp. 675-682
Authors:
Caforio, ALP
Goldman, JH
Baig, MK
Mahon, NJ
Haven, AJ
Souberbielle, BE
Holt, DW
Dalgleish, AG
McKenna, WJ
Citation: Alp. Caforio et al., Elevated serum levels of soluble interleukin-2 receptor, neopterin and beta-2-microglobulin in idiopathic dilated cardiomyopathy: relation to diseaseseverity and autoimmune pathogenesis, EUR J HE FA, 3(2), 2001, pp. 155-163
Authors:
Eaton, JD
Perry, MJA
Todryk, SM
Mazucco, RA
Kirby, RS
Griffiths, JR
Dalgleish, AG
Citation: Jd. Eaton et al., Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques, GENE THER, 8(7), 2001, pp. 557-567
Authors:
Pettersson, F
Colston, KW
Dalgleish, AG
Citation: F. Pettersson et al., Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells, PANCREAS, 23(3), 2001, pp. 273-279
Authors:
Koopman, G
Dalgleish, AG
Bhogal, BS
Haaksma, AGM
Heeney, JL
Citation: G. Koopman et al., Changes in dendritic cell subsets in the lymph nodes or rhesus macaques after application of glucocorticoids, HUMAN IMMUN, 62(3), 2001, pp. 208-214
Authors:
O'Byrne, KJ
Dalgleish, AG
Citation: Kj. O'Byrne et Ag. Dalgleish, Infection and cancer - Reply, LANCET, 358(9276), 2001, pp. 156-156
Authors:
Todryk, SM
Tutt, AL
Green, MHA
Smallwood, JA
Halanek, N
Dalgleish, AG
Glennie, MJ
Citation: Sm. Todryk et al., CD40 ligation for immunotherapy of solid tumours, J IMMUNOL M, 248(1-2), 2001, pp. 139-147
Authors:
Dalgleish, AG
Citation: Ag. Dalgleish, Current problems in the development of specific immunotherapeutic approaches to cancer, J CLIN PATH, 54(9), 2001, pp. 675-676
Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines
Authors:
Todryk, SM
Birchall, LJ
Erlich, R
Halanek, N
Orleans-Lindsay, JK
Dalgleish, AG
Citation: Sm. Todryk et al., Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines, IMMUNOLOGY, 102(2), 2001, pp. 190-198
Authors:
Marriott, JB
Clarke, IA
Dalgleish, AG
Citation: Jb. Marriott et al., Inhibition of p38 MAP kinase during cellular activation results in IFN-gamma-dependent augmentation of IL-12 production by human monocytes/macrophages, CLIN EXP IM, 125(1), 2001, pp. 64-70
Authors:
Hrouda, D
Todryk, SM
Perry, MJA
Souberbielle, BE
Kayaga, J
Kirby, RS
Dalgleish, AG
Citation: D. Hrouda et al., Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer, BJU INT, 86(6), 2000, pp. 742-748
Authors:
Dalgleish, AG
Perry, MJA
Eaton, JD
Hrouda, D
Todryk, SM
Kirby, RS
Citation: Ag. Dalgleish et al., The immunotherapy of prostate cancer, PROSTATE C, 3(4), 2000, pp. 303-307
Authors:
Scott-Taylor, TH
Dalgleish, AG
Citation: Th. Scott-taylor et Ag. Dalgleish, DNA vaccines, EXPERT OP I, 9(3), 2000, pp. 471-480
Authors:
Szlosarek, PW
Dalgleish, AG
Citation: Pw. Szlosarek et Ag. Dalgleish, Potential applications of gene therapy in the patient with cancer, DRUG AGING, 17(2), 2000, pp. 121-132
Authors:
Perry, MJA
Hrouda, D
Dalgleish, AG
Citation: Mja. Perry et al., Prospects for vaccination in prostate cancer, DRUG AGING, 16(5), 2000, pp. 321-327
Authors:
de Bono, JS
Dalgleish, AG
Carmichael, J
Diffley, J
Lofts, FJ
Fyffe, D
Ellard, S
Gordon, RJ
Brindley, CJ
Evans, TRJ
Citation: Js. De Bono et al., Phase I study of ONO-4007, a synthetic analogue of the lipid a moiety of bacterial lipopolysaccharide, CLIN CANC R, 6(2), 2000, pp. 397-405
Authors:
Dalgleish, AG
Citation: Ag. Dalgleish, Tumour markers in malignancies - CA19.9 is useful in several cancers ..., BR MED J, 321(7257), 2000, pp. 380-380
Authors:
O'Byrne, KJ
Dalgleish, AG
Browning, MJ
Steward, WP
Harris, AL
Citation: Kj. O'Byrne et al., The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease, EUR J CANC, 36(2), 2000, pp. 151-169
Authors:
Scott-Taylor, TH
Pettengell, R
Clarke, I
Stuhler, G
La Barthe, MC
Walden, P
Dalgleish, AG
Citation: Th. Scott-taylor et al., Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines, BBA-MOL BAS, 1500(3), 2000, pp. 265-279
Authors:
Shearer, MH
Dalgleish, AG
Chanh, TC
Kennedy, RC
Citation: Mh. Shearer et al., Idiotype cascades associated with the CD4-HIV glycoprotein 120 interaction: Immunization with anti-idiotypic antibodies induces anti-anti-idiotypic responses with anti-CD4 specificity and in vitro neutralizing activity, AIDS RES H, 16(1), 2000, pp. 77-86
Authors:
Sheikh, J
Souberbielle, B
Westby, M
Austen, B
Dalgleish, AG
Citation: J. Sheikh et al., HIV gp120 plus specific peptides are recognized in a similar manner to specific HLA plus peptide by HLA-restricted antigen-specific T-cell lines, VIRAL IMMUN, 13(1), 2000, pp. 9-17
Authors:
John, J
Pandha, H
Dalgleish, AG
Citation: J. John et al., Detection of T cell cytokine production as a tool for monitoring immunotherapy, DIS MARKER, 16(1-2), 2000, pp. 71-75
Authors:
O'Byrne, KJ
Dalgleish, AG
Citation: Kj. O'Byrne et Ag. Dalgleish, Evolution, immune response, and cancer, LANCET, 356(9234), 2000, pp. 1033-1034
Authors:
Todryk, SM
Melcher, AA
Dalgleish, AG
Vile, RG
Citation: Sm. Todryk et al., Heat shock proteins refine the danger theory, IMMUNOLOGY, 99(3), 2000, pp. 334-337
Authors:
Guckian, M
Dransfield, I
Hay, P
Dalgleish, AG
Citation: M. Guckian et al., Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro, CLIN EXP IM, 121(3), 2000, pp. 472-479